Literature DB >> 22447314

Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria.

Francesca Menni1, Sara Testa, Sophie Guez, Gabriella Chiarelli, Luisella Alberti, Susanna Esposito.   

Abstract

BACKGROUND: Inborn errors of cobalamin (Cbl) absorption and metabolism form a large group of rare diseases that include Cbl-C disorder. Among the renal complications of Cbl-C disorder, atypical hemolytic uremic syndrome (HUS) is the least common and has been described only in a small number of cases. CASE-DIAGNOSIS/TREATMENT: Four patients were admitted to our clinic after 15-30 days of life with vomiting associated with poor sucking, failure to thrive, lethargy and hypotonia. Examinations showed thrombocytopenia and microangiopathic hemolytic anemia associated with renal damage. The neonates had high blood homocysteine levels, increased urinary levels of both homocystine and methylmalonic acid, increased propionylcarnitine (C3) levels and an increased C3/acetylcarnitine ratio. Homozygosity for c.271-272dupA (p.Arg91LysfsX14) of the MMACHC gene was detected in three patients, and heterozygosity for c.271-272dupA and c.666C > A(p.Tyr222X) in one patient, which confirmed the diagnosis of Cbl-C disorder. Treatment with parenteral hydroxycobalamin in combination with folic acid and betaine gradually normalized the metabolic test findings and hematological and renal parameters after about 1 week.
CONCLUSIONS: Atypical HUS in neonates with Cbl-C disorder may be associated with mild to moderate renal involvement also in early-onset disease, and early adequate therapy can reverse renal damage.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22447314     DOI: 10.1007/s00467-012-2152-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  15 in total

Review 1.  Acute kidney injury: classification and staging.

Authors:  Dinna N Cruz; Sean M Bagshaw; Claudio Ronco; Zaccaria Ricci
Journal:  Contrib Nephrol       Date:  2010-04-20       Impact factor: 1.580

2.  Methylmalonic acidemia: 6 years' clinical experience with two variants unresponsive to vitamin B12 therapy.

Authors:  D T Whelan; E Ryan; M Spate; M Morris; R M Hurley; R Hill
Journal:  Can Med Assoc J       Date:  1979-05-19       Impact factor: 8.262

3.  Cobalamin C defect presenting as severe neonatal hyperammonemia.

Authors:  Diego Martinelli; Andrea Dotta; Laura Massella; Stefano Picca; Alessandra Di Pede; Sara Boenzi; Chiara Aiello; Carlo Dionisi-Vici
Journal:  Eur J Pediatr       Date:  2010-12-10       Impact factor: 3.183

Review 4.  Cobalamin C defect: natural history, pathophysiology, and treatment.

Authors:  Diego Martinelli; Federica Deodato; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2010-07-15       Impact factor: 4.982

5.  Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte.

Authors:  James D Weisfeld-Adams; Mark A Morrissey; Brian M Kirmse; Bobbie R Salveson; Melissa P Wasserstein; Peter J McGuire; Sherlykutty Sunny; Jessica L Cohen-Pfeffer; Chunli Yu; Michele Caggana; George A Diaz
Journal:  Mol Genet Metab       Date:  2009-09-27       Impact factor: 4.797

6.  Clinical and molecular heterogeneity in patients with the cblD inborn error of cobalamin metabolism.

Authors:  Isabelle R Miousse; David Watkins; David Coelho; Tony Rupar; Eric A Crombez; Eric Vilain; Jonathan A Bernstein; Tina Cowan; Christopher Lee-Messer; Gregory M Enns; Brian Fowler; David S Rosenblatt
Journal:  J Pediatr       Date:  2008-12-05       Impact factor: 4.406

7.  Spectrum of MMACHC mutations in Italian and Portuguese patients with combined methylmalonic aciduria and homocystinuria, cblC type.

Authors:  Célia Nogueira; Chiara Aiello; Roberto Cerone; Esmeralda Martins; Ubaldo Caruso; Isabella Moroni; Cristiano Rizzo; Luísa Diogo; Elisa Leão; Fernando Kok; Federica Deodato; Maria Cristina Schiaffino; Sara Boenzi; Olivier Danhaive; Clara Barbot; Sílvia Sequeira; Mattia Locatelli; Filippo M Santorelli; Graziella Uziel; Laura Vilarinho; Carlo Dionisi-Vici
Journal:  Mol Genet Metab       Date:  2007-12-27       Impact factor: 4.797

8.  Spectrum of mutations in MMACHC, allelic expression, and evidence for genotype-phenotype correlations.

Authors:  Jordan P Lerner-Ellis; Natascia Anastasio; Junhui Liu; David Coelho; Terttu Suormala; Martin Stucki; Amanda D Loewy; Scott Gurd; Elin Grundberg; Chantal F Morel; David Watkins; Matthias R Baumgartner; Tomi Pastinen; David S Rosenblatt; Brian Fowler
Journal:  Hum Mutat       Date:  2009-07       Impact factor: 4.878

9.  Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen.

Authors:  J S Stamler; J A Osborne; O Jaraki; L E Rabbani; M Mullins; D Singel; J Loscalzo
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

10.  Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy.

Authors:  Johan L K Van Hove; Rita Van Damme-Lombaerts; Stephanie Grünewald; Heidi Peters; Boudewijn Van Damme; Jean-Pierre Fryns; Jozef Arnout; Ron Wevers; E Regula Baumgartner; Brian Fowler
Journal:  Am J Med Genet       Date:  2002-08-01
View more
  15 in total

1.  Thrombotic microangiopathy caused by methionine synthase deficiency: diagnosis and treatment pitfalls.

Authors:  Maria Helena Vaisbich; Andressa Braga; Maria Gabrielle; Clarissa Bueno; Flávia Piazzon; Fernando Kok
Journal:  Pediatr Nephrol       Date:  2017-02-16       Impact factor: 3.714

Review 2.  Current treatment of atypical hemolytic uremic syndrome.

Authors:  Bernard S Kaplan; Rebecca L Ruebner; Joann M Spinale; Lawrence Copelovitch
Journal:  Intractable Rare Dis Res       Date:  2014-05

Review 3.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

4.  Nephrotic syndrome and thrombotic microangiopathy caused by cobalamin C deficiency.

Authors:  Jens C Koenig; Frank Rutsch; Clemens Bockmeyer; Matthias Baumgartner; Bodo B Beck; Brigitta Kranz; Martin Konrad
Journal:  Pediatr Nephrol       Date:  2015-04-18       Impact factor: 3.714

5.  Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab.

Authors:  Nesrin Besbas; Bora Gulhan; Diana Karpman; Rezan Topaloglu; Ali Duzova; Emine Korkmaz; Fatih Ozaltin
Journal:  Pediatr Nephrol       Date:  2012-09-06       Impact factor: 3.714

6.  Remission of aHUS neurological damage with eculizumab.

Authors:  Ana Ávila; Belén Vizcaíno; Pablo Molina; Eva Gavela; Maria Perez-Ebri; Luís Pallardó
Journal:  Clin Kidney J       Date:  2015-01-22

Review 7.  Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency.

Authors:  Martina Huemer; Daria Diodato; Bernd Schwahn; Manuel Schiff; Anabela Bandeira; Jean-Francois Benoist; Alberto Burlina; Roberto Cerone; Maria L Couce; Angeles Garcia-Cazorla; Giancarlo la Marca; Elisabetta Pasquini; Laura Vilarinho; James D Weisfeld-Adams; Viktor Kožich; Henk Blom; Matthias R Baumgartner; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2016-11-30       Impact factor: 4.982

8.  Late Onset Cobalamin Disorder and Hemolytic Uremic Syndrome: A Rare Cause of Nephrotic Syndrome.

Authors:  Gianluigi Ardissino; Michela Perrone; Francesca Tel; Sara Testa; Amelia Morrone; Ilaria Possenti; Francesco Tagliaferri; Robertino Dilena; Francesca Menni
Journal:  Case Rep Pediatr       Date:  2017-08-01

Review 9.  Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity.

Authors:  Bodo B Beck; FrancJan van Spronsen; Arjan Diepstra; Rolf M F Berger; Martin Kömhoff
Journal:  Pediatr Nephrol       Date:  2016-06-11       Impact factor: 3.714

10.  Parenteral hydroxocobalamin dose intensification in five patients with different types of early onset intracellular cobalamin defects: Clinical and biochemical responses.

Authors:  Emmanuel Scalais; Elise Osterheld; Christine Geron; Charlotte Pierron; Ronit Chafai; Vincent Schlesser; Patricia Borde; Luc Regal; Hilde Laeremans; Koen L I van Gassen; L Bert van den Heuvel; Linda De Meirleir
Journal:  JIMD Rep       Date:  2019-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.